As the Pfizer-Allergan merger talks heat up, shining yet another spotlight on the tax inversion issue, a Goldman Sachs report notes that it is up to the U.S. Treasury and IRS to stem flood of corporations fleeing the U.S. tax system for more friendly climates abroad. Pfizer / Allergan acquisition would result in a tax inversion, as clock is ticking If drug giant Pfizer Inc. is successful in its talk to acquire Allergan Plc, the result of the $150 billion deal would mean the New Jersey-based corporation would pay its tax in Ireland. The clock is ticking as the Treasury…
Tax Inversion Action? Clock Ticks on Pfizer-Allergan Merger
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.